Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (625)	2/27/1999 2:23:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 1073

Rick, Some relevant (?) Medarex research <<These data demonstrate that human FcRI on myeloid cells is highly active in mediating enhanced antigen presentation in vivo, and show that anti-FcgammaRI mAbs are promising vaccine adjuvants. (J. Clin. Invest. 1996. 97:331-338.) >> Full text at: jci.org (still free at JCI; PDF also available) Regarding this part of your post: <<So, MEDX went later to the step of stimulating the production of Fc-receptor positive effectors before administration of the bispecific. >> I understand they use GM-CSF to achieve this. They have also published a few articles exploring the use of anti-Fc-ALPHA-receptor antibodies to increase the potential (targeted) cytotoxic effect of putative bispecifics using this kind of arm. Not sure if the latter will need the stimulation step you refer to above? Should one worry that these bispecifics do not have Fc portions (they are Fab'2-like, for the aficionados -g-), and thus have much lower serum half-life than "honest" antibodies such as Rituxan or Herceptin? Hoping this is still kind of "on topic," PB